Current Diabetes Trials

Daniel Nadeau, M.D., Program Director of the Mary & Dick Allen Diabetes Center at Hoag Hospital Memorial Presbyterian and Dr. Kris V. Iyer Endowed Chair in Diabetes Care, is the principal investigator for two diabetes trials at Hoag Medical Group.

Type 1 Diabetes Trial

Hoag Medical is enrolling patients with type 1 diabetes in a new clinical trial. The onset®8 is a clinical research trial evaluating a new investigational faster-acting insulin to see if it can provide improved blood glucose control in adults with type 1 diabetes.

Patients may be eligible to join the study if they:

  • Are 18 years of age or older
  • Have been diagnosed with type 1 diabetes for at least 1 year
  • Are currently treated with both meal time insulin and long-acting insulin
  • Have an HbA1c between 7.0-9.5%

What are the benefits of being involved in the onset®8 trial?

  • Comprehensive care, including regular health checks and medical testing
  • Access to trial medication and blood glucose testing equipment
  • You may be compensated for your time and travel

Type 2 Diabetes Trial

Hoag Medical Group is currently enrolling patients in a study to evaluate the effect of Farxiga on blood glucose level and renal safety in patients with type 2 diabetes mellitus and reduced kidney function. Farxiga is approved by the US FDA for the treatment of type 2 diabetes, but not approved by the FDA for the treatment of type 2 diabetes in people with moderate renal disease. The purpose of this study is to find out if Farxiga is effective in decreasing blood glucose level, body weight and blood pressure, when it is added to existing diabetes therapy and whether it causes any side effects in adult patients with moderate renal disease (renal impairment) with Type 2 diabetes mellitus, who are not currently in good glucose control.

Patients may be eligible to join the study if they:

  • Have a history of Type 2 diabetes mellitus for more than 12 months
  • Female or male aged ≥18 years and <75 years
  • Have an HbA1c ≥ 7.0% and ≤ 11%
  • Have renal impairment with an eGFR 40-65 mL/minute/1.73m2

For more information or to schedule a study appointment please call the HMG Research Department at 949-791-3049.